Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost per patient has soared from $500 to $250,000 in past decade, Memorial-Sloan Kettering Research says. It would cost $7.5 bil. to treat all colorectal cancer patients unless some restraints are put in place.
You may also be interested in...
Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies
Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said
Combination Use Of Targeted Cancer Therapies Advancing Since ASCO, Roche Says
The debate surrounding the cost of novel cancer treatments can be validated by "solid data," Roche Pharmaceuticals Head Burns says. The firm is confident that the positioning of its products, including Genentech's Avastin, is "defensible."